Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.

摘要: Background Patients with metastatic, progressive or recurrent Ewing sarcoma (ES) have a dismal outcome. The combination of irinotecan and temozolomide has been proposed as an effective salvage regimen for some pediatric malignancies. Thus, we sought to evaluate this vincristine patients relapsed refractory ES. Materials Methods Twenty-two ES were treated the (1.5 mg/m2 i.v. day 1), (50 mg/m2/day days 1–5) (125 mg/m2/day p.o. (VIT) during period 2008–2012. All toxicities documented. Results A total 91 cycles (median 4.1 cycles/patient) administered. A complete response (CR) was achieved in five patients, partial (PR) seven stable disease (SD) three progression (PD) overall rate 68.1%. Median time 3.0 months (range 1.1–37.1 months). Five (22.7%) are alive no evidence median follow-up 10.3 2.1–46.5); four them received consolidation high-dose chemotherapy autologous hematopoietic stem cell transplant after responding VIT. Outcome better compared who progressed initial therapy (estimated 2 year survival 36.4% vs. 0%, respectively). There significant toxicities. Conclusions The shorter, 5-day VIT is active well-tolerated ES. This deserves further investigation upfront management metastatic disease. Pediatr Blood Cancer 2013;60:1621–1625. © 2013 Wiley Periodicals, Inc.